Who Paid My Doc
Octaplas
Biological Intensive Careemergency
NDC 68982-952-01
General payments
$49,932
Research payments
$163,680
Through program year 2025, $49,932 in general payments and $163,680 in research payments were reported against Octaplas (Intensive Careemergency).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
9 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $5,000 | 1 |
| 2024 | General | $5,000 | 1 |
| 2023 | General | $6,790 | 11 |
| 2022 | General | $1,433 | 15 |
| 2021 | General | $165 | 3 |
| 2020 | General | $7,464 | 41 |
| 2020 | Research | $63,365 | 5 |
| 2019 | General | $24,080 | 147 |
| 2019 | Research | $100,315 | 22 |
Breakdown
Each share is of general payments naming this product in 2025.
Each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
Each share is of general payments naming this product in 2025 where a state was reported.
Records
219 general · 27 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.